NCT03993379 2025-12-26
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
CytomX Therapeutics
Phase 2 Terminated
CytomX Therapeutics
CytomX Therapeutics
GlaxoSmithKline
Jounce Therapeutics, Inc.
SQZ Biotechnologies
RAPT Therapeutics, Inc.
Bristol-Myers Squibb
Bristol-Myers Squibb
Ludwig Institute for Cancer Research
AbbVie
Incyte Corporation